Threshold NeuroDiagnostics Secures Patent for Medusa Electrode Device

Stealth startup neural interface company, Threshold NeuroDiagnositcs has received a patient (No. 11904169) for its Medusa Electrode. The Medusa Electrode is FDA-registered Class II (exempt) and bridges neuromodulation electrodes with neurodiagnostic equipment and artificial intelligence. 
 
This device translates manufacturer-specific neuromodulation connections into universal EEG plugs. The Medusa Electrode creates a cost-effective solution by allowing access to more than 70,000 invasive electrodes per year in the US. It can be used for biomarker access, anatomical localization, and expanding research opportunities. 
 
Plugs are converted to universal 1.5 DIN connectors, enabling seamless integration between the neurophysiology equipment and the nervous system. The Medusa Electrode improves access to Class III invasive neuromodulation electrodes to expand medical professionals’ neurodiagnostic capabilities, enhancing research and clinical applications. 
 
This device allows neuromodulation companies to diversify their markets, provides doctors with a wide variety of solutions for treating patients, and delivers treatment options to a large segment of patients where treatments are not available or cost-prohibited. 
 
“Our goal is to leverage the human neural network to address a broad spectrum of neurological issues, and securing this patent is a key milestone in that journey,” said Geoffrey Allott, Founder of Threshold NeuroDiagnostics. “We aim to quickly evaluate hypotheses, analyze responses, and develop effective solutions, bypassing regulatory hold-ups, unnecessary expenses, and ethical issues. The Medusa Electrode is an integral step in creating ‘closed-loop’ neuromodulation systems, similar to a ‘nervous system pacemaker,’ demonstrates our focus on creating simple and flexible solutions that have a profound impact on neuromodulation research and therapies.”
 
With the Medusa Electrode, research centers have been able to develop cures for depression, treat obsessive-compulsive disorders, reduce binge eating, and help treat other psychiatric illnesses. Next-generation neuroprosthetics have also been developed using the Medusa Electrode, providing sensory and motor control for artificial limbs, and neuromodulation-assisted respiration devices.  It is also being used for a wide variety of peripheral devices for hemodynamic, bowel, gastrointestinal, and bladder function.
 
Threshold NeuroDiagnostics aims to lower the cost of development for a wide range of neuromodulation products for underserved markets.  The company is currently seeking partners to broaden the Medusa Electrode’s compatibility and applications.